Increasing evidence indicates that patients or experimental animals exposure to
endotoxin (
lipopolysaccharides, LPS) exert deleterious cardiac functions that greatly contribute to morbidity and mortality. The pathophysiologic processes, including NLRP3
inflammasome overactivation and cardiac inflammatory injury, are complicated.
Sodium tanshinone IIA sulfonate (STS), a water-soluble derivative of
tanshinone IIA, is a naturally occurring compound extracted from Salvia miltiorrhiza and has anti-inflammatory and cardioprotective properties. In this study we examined the effect of STS on
endotoxin-induced
cardiomyopathy and investigated the underlying mechanisms. An endotoxemic mouse model was established by injecting LPS (10 mg/kg). Different doses of STS were administered intraperitoneally (5, 10, or 50 mg/kg) at different time points (2/12 h, 4/12 h, and 8/12 h) after LPS challenge to assess its effect on survival of mice with
endotoxemia. In parallel, cardiac function, myocardial inflammatory
cytokines, cardiomyocyte pyroptosis and autophagy were evaluated to determine the extent of myocardial damage due to
sepsis in the presence and absence of STS at the optimal dose (10 mg/kg) and time-point (2/12 h). The results demonstrated that STS increased the survival rates, improved the compromised cardiac function and reduced myocardial inflammatory injury associated with enhanced autophagy and mitigated NLRP3
inflammasome activation. Moreover, inhibiting of autophagy or blocking the AMPK pathway reversed STS-elicited prevention of
cardiomyopathy and activated the NLRP3
inflammasome in endotoxemic mice. Collectively, our study demonstrates that STS attenuates
endotoxemia-induced mortality and
cardiomyopathy, which may be associated with promotion of autophagy and inhibition of NLRP3
inflammasome overactivation.